First Confirmed Case of Underage E-cigarette Related Lung Disease in Costa Rica

News by 2FIRSTS.ai
Nov.17.2023
First Confirmed Case of Underage E-cigarette Related Lung Disease in Costa Rica
Costa Rica reports its first confirmed case of a minor with e-cigarette related lung disease, raising concerns over its safety.

According to a report on November 15 from CNN Spain, the Social Security Fund of Costa Rica (Caja Costarricense de Seguro Social) has recently issued a statement confirming the country's first case of an e-cigarette related lung disease in a minor.

 

According to a report by the organization, a 16-year-old minor has been using e-cigarettes without supervision on a regular basis. As a result, the individual had to spend 29 days in the intensive care unit for treatment, during which mechanical ventilation and intubation were necessary. The organization highlights this case to remind the public once again that e-cigarettes are not harmless and are not a smoking cessation method, as they can potentially be fatal.

 

According to the institution's statistics, the number of cases related to e-cigarette-associated illnesses in the Costa Rican public healthcare system has risen significantly, from 13 cases in the entire year of 2021 to 857 cases in the first half of 2023. The majority of these cases are reported from clinics in the central region of the country.

 

In addition, the results of the 2021 National Survey on the Consumption of Psychotropic Substances among the population of secondary education, published by the Institute on Alcoholism and Drug Dependence (IAFA) in Costa Rica, reveal a significant increase in the proportion of students who have experimented with nicotine or e-cigarette products, reaching 13.1%. This percentage is nearly triple the findings from the previous survey conducted in 2018 (4.6%).

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Azerbaijan’s Milli Majlis passes final reading bill banning e-cigarettes and their components
Azerbaijan’s Milli Majlis passes final reading bill banning e-cigarettes and their components
Azerbaijan’s Milli Majlis adopted in final reading a bill banning the import, export, production, storage, wholesale and retail sale, and use of electronic cigarettes and their components, through amendments to the law On Tobacco and Tobacco Products. The document states that nicotine-containing electronic cigarettes are included within the concept of tobacco products and sets out a definition of electronic cigarettes.
Dec.31 by 2FIRSTS.ai
BAT’s Vuse Ultra listed as GOOD DESIGN Awards winner; features app connectivity and adjustable intensity
BAT’s Vuse Ultra listed as GOOD DESIGN Awards winner; features app connectivity and adjustable intensity
British American Tobacco’s (BAT) Vuse Ultra vaping product has been listed among winners on the U.S. GOOD DESIGN Awards website, in the “Personal Experience” category, according to the project page. The page identifies the award year as 2025 and names BAT (London) as both the entrant and the manufacturer.
Jan.20 by 2FIRSTS.ai
Russia’s Volgograd Police Seize Illicit Nicotine Products Worth Over US$42.9K+
Russia’s Volgograd Police Seize Illicit Nicotine Products Worth Over US$42.9K+
Police in Russia’s Volgograd region say they seized nicotine products lacking mandatory markings valued at more than RUB 3.3 million (about US$42,900+, using RUB 1 = US$0.013). A 43-year-old suspect allegedly stored and sold the products through two retail outlets in Volgograd’s Central and Dzerzhinsky districts. A criminal case has been opened under Article 171.1(6) of the Russian Criminal Code.
Jan.30 by 2FIRSTS.ai
Russian consumer group urges Kremlin administration to reject regional vape sales bans
Russian consumer group urges Kremlin administration to reject regional vape sales bans
A Russian consumer organization has urged the Presidential Administration to block proposals that would let regions ban ENDS and e-liquid sales, warning it would create fragmented regulation and turbocharge the illicit market. The group cites WHO statistics and overseas experiences to argue for a more targeted regulatory model.
Feb.06 by 2FIRSTS.ai
Liverpool City Region Considers Healthier Advertising Rules for Trains, Ferries and Buses — Vapes Included
Liverpool City Region Considers Healthier Advertising Rules for Trains, Ferries and Buses — Vapes Included
The Liverpool City Region is considering a region-wide clampdown on advertising for junk food, sugary drinks and vapes on publicly owned infrastructure. The move is framed as part of a broader push to promote healthier lifestyles and tackle deep-rooted health inequalities, with a particular focus on reducing children’s exposure to harmful marketing in public spaces. The plan is set to go before the Combined Authority on Friday.
Jan.23 by 2FIRSTS.ai